Short-Term Cost per Responder of Lebrikizumab versus Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Model-Based Payer Analysis. (PubMed, Clinicoecon Outcomes Res) - Sep 28, 2026 - "The pruritus result was exploratory and changed according to the cost horizon and pack-purchasing convention; it does not establish a consistent economic advantage for either treatment. The findings are price dependent and should not be interpreted as overall clinical superiority or long-term cost-effectiveness."
Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus
|